MBX Biosciences, Inc. Capital Expenditures Incurred but Not yet Paid
MBX Biosciences, Inc. (MBX) reported Capital Expenditures Incurred but Not yet Paid of $733.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- MBX Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $709.00K.
- MBX Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $24.00K, a 95.22% decline year-over-year.
- MBX Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $21.00K, a 61.54% increase year-over-year.
- MBX Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$2.00K.
- MBX Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $26.00K, a 10.34% decline from fiscal 2024.
- MBX Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $29.00K, a 61.11% increase from fiscal 2023.
- MBX Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $18.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $709.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $733.00K 10-Q · filed 2026-08-06 | $754.00K derived: sum of 3 quarters · filed 2026-08-06 | $752.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $24.00K 10-Q · filed 2026-05-07 | $45.00K derived: sum of 2 quarters · filed 2026-05-07 | $43.00K derived: sum of 3 quarters · filed 2026-05-07 | -$452.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $19.00K derived: sum of 2 quarters · filed 2026-03-12 | -$476.00K derived: sum of 3 quarters · filed 2026-08-06 | $26.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$497.00K derived: sum of 2 quarters · filed 2026-08-06 | $5.00K 10-Q · filed 2025-11-06 | $18.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$495.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.00K 10-Q · filed 2026-08-06 | $20.00K derived: sum of 3 quarters · filed 2026-08-06 | -$34.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $502.00K 10-Q · filed 2026-05-07 | $515.00K derived: sum of 2 quarters · filed 2026-05-07 | $461.00K derived: sum of 3 quarters · filed 2026-05-07 | $497.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$41.00K derived: sum of 2 quarters · filed 2026-03-12 | -$5.00K derived: sum of 3 quarters · filed 2026-03-12 | $29.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$54.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$18.00K derived: sum of 2 quarters · filed 2025-11-06 | $16.00K 10-Q · filed 2025-11-06 | $34.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $70.00K 10-Q · filed 2025-08-07 | $88.00K derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $34.00K 10-Q · filed 2025-05-12 | $52.00K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $18.00K 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |